Julphar announces Q3 2017 results


Julphar reaches sales amounting to AED 992 million with a net profit of AED 86 million


Julphar, one of the largest pharmaceutical manufacturer in Middle East and North Africa, announced today a revenue of AED 992 million for the first three quarters of the year 2017. The company posted a net profit for the period of AED 86 million.
“Overall, the MENA markets remained challenging for the pharmaceutical industry. Julphar’s management has undertaken cost saving initiatives and new projects to further optimize processes and consolidate our current market shares. We will continue to launch our new products pipeline while increasing our geographical presence, in order to fully align towards with our 2020 roadmap” said Jerome Carle, Julphar General Manager. 
“Saudi Arabia remains the major revenue contributor for Julphar, despite the current market situation in the Kingdom. At the same time, the UAE operations achieved a solid growth of 16%. With steady double-digit growth, the performance of the North African and Levant regions confirms Julphar as a strategic player in the area”.
This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, refer to our Cookie Policy.